WEST PHARMACEUTIC.SERVICES INC

ISIN: US9553061055 WKN: 955306105 Asset Class: Stock



Company Profile

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets I	iabilities and equity	
Current assets	1,936,400,000		1,919,500,000		1,742,000,000		
Common stock capital		18,800,000		18,800,000		18,800,000	
Fixed assets	1,893,100,000		1,697,300,000		1,571,800,000		
Equity capital of a company		2,881,000,000		2,684,900,000		2,335,400,000	
Cash and cash equivalents	853,900,000		894,300,000		762,600,000		
Accrued liabilities		29,600,000		47,300,000		69,400,000	
Other assets	-		-		-		
Current liabilities		671,800,000		519,000,000		594,100,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		276,700,000		412,900,000		384,300,000	
Different income		-		-		-	
Other liabilities		77,100,000		51,600,000		38,200,000	
Total assets	3,829,500,000	3,829,500,000	3,616,800,000	3,616,800,000	3,313,800,000	3,313,800,000	

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	10,600	10,700	10,065
Equity ratio	75.23%	74.23%	70.47%
Debt-equity ratio	32.92%	34.71%	41.89%

Others

	2023	2022	2021
Tax Expense Rate	17.52%	16.87%	14.31%

WEST PHARMACEUTIC.SERVICES INC

ISIN: US9553061055 WKN: 955306105 Asset Class: Stock

Income statement

	2023	2022	2021
	2023	2022	2021
Turnover	2,951,100,000	2,885,500,000	2,830,700,000
Net income	593,400,000	585,900,000	661,800,000
EBIT	632,845,240	639,651,030	707,056,320
Operating income before taxes	698,000,000	679,900,000	748,900,000
Cash Flow	776,500,000	724,000,000	584,000,000
Net interest income	19,200,000	-6,200,000	-9,500,000
Research and development expenses	68,400,000	58,500,000	52,800,000
Income taxes	122,300,000	114,700,000	107,200,000
Result from investments in subsidaries, associates and other	17,700,000	20,700,000	20,100,000
Revenues per employee	259,558	251,416	262,202

Board of Directors

Members of Management Board

Myla Lai-Goldman	Member of Board of Directors
Stephen Lockhart	Member of Board of Directors
William Feehery	Member of Board of Directors
Deborah Keller	Member of Board of Directors
Douglas Michels	Member of Board of Directors
Mark Buthman	Member of Board of Directors
Molly Joseph	Member of Board of Directors
Paolo Pucci	Member of Board of Directors
Robert Friel	Member of Board of Directors
Thomas Hofmann	Member of Board of Directors
Eric M. Green	Chairman of Managing Board
Quintin Lai	Member of Executive Committee
Andy Polywacz	Member of Executive Committee
Annette F. Favorite	Member of Executive Committee
Bernard J. Birkett	Member of Executive Committee
Chris Ryan	Member of Executive Committee
Cindy Reiss-Clark	Member of Executive Committee
David A. Montecalvo	Member of Executive Committee
Kimberly Banks MacKay	Member of Executive Committee
Silji Abraham	Member of Executive Committee